WILMINGTON, Del., July 17, 2026
Incyte has announced that it will present six oncology studies, including four rapid oral presentations, at the European Society for Medical Oncology (ESMO) Congress 2026, scheduled for October 23–27, 2026, in Madrid, Spain. The presentations will highlight new clinical data from the company’s solid tumor portfolio, demonstrating continued progress in developing innovative therapies for patients with difficult-to-treat cancers. Key updates include investigational programs targeting KRAS G12D, TGFβR2×PD-1, and CDK2, alongside a Phase 3 survival analysis for retifanlimab in advanced squamous anal cancer. According to Pablo J. Cagnoni, M.D., President and Global Head of Research and Development at Incyte, the upcoming presentations reinforce the company’s commitment to advancing precision oncology and addressing cancers with significant unmet medical needs. The featured investigational therapies are designed to improve outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC), microsatellite stable colorectal cancer (MSS CRC), recurrent epithelial ovarian cancer, and other aggressive malignancies through targeted and combination treatment approaches.
Rapid Oral Presentations Highlight Phase 1 Precision Oncology Programs
The centerpiece of Incyte’s ESMO 2026 participation will be four rapid oral presentations showcasing early clinical progress across multiple targeted oncology candidates. Among the most anticipated presentations is INCB161734, an investigational oral KRAS G12D inhibitor, which will report safety and efficacy data both as monotherapy or in combination with cetuximab for patients with advanced or metastatic colorectal cancer, and in combination with chemotherapy for patients with advanced or metastatic pancreatic ductal adenocarcinoma. Incyte will also present new findings for INCA338901, a TGFβR2×PD-1 bispecific antibody, being evaluated with standard-of-care therapies for microsatellite stable colorectal cancer, a disease that has historically demonstrated limited responsiveness to immunotherapy. Another rapid oral presentation will feature INCB123667, a selective CDK2 inhibitor, evaluating preliminary efficacy when combined with bevacizumab for recurrent epithelial ovarian cancer. Together, these studies demonstrate Incyte’s strategy of combining targeted therapies, immuno-oncology, and precision medicine to improve outcomes across multiple solid tumor indications.
Phase 3 Programs Expand Development Across Multiple Solid Tumors
Several of the investigational therapies featured at ESMO have already advanced into Phase 3 clinical development, reflecting growing confidence in their therapeutic potential. INCB161734 is currently being evaluated in an ongoing Phase 3 program as a first-line treatment for patients with advanced pancreatic ductal adenocarcinoma, while INCA338901 has progressed into Phase 3 evaluation for first-line microsatellite stable colorectal cancer, one of the largest populations with limited immunotherapy benefit. Beyond the rapid oral presentations, Incyte will also present a poster featuring the final overall survival analysis from the POD1UM-303 (InterAACT-2) Phase 3 study, evaluating retifanlimab in combination with carboplatin and paclitaxel for first-line advanced squamous anal cancer. Another poster will highlight the design of the MAESTRA 3 (GOG-3146/ENGOT-OV106) Phase 3 trial, assessing INCB123667 combined with bevacizumab as maintenance therapy for patients with Cyclin E1-overexpressing advanced epithelial ovarian, fallopian tube, and primary peritoneal cancers.
Advertisement
Broad Oncology Portfolio Reinforces Incyte’s Precision Medicine Strategy
The extensive data being presented at ESMO Congress 2026 reflects Incyte’s expanding oncology pipeline and continued investment in therapies targeting genetically defined cancers with limited treatment options. By advancing KRAS G12D inhibitors, bispecific antibodies, CDK2 inhibitors, and immune checkpoint therapies, the company is building a diversified portfolio aimed at improving treatment across gastrointestinal, gynecologic, and other solid tumors. The presentations also demonstrate Incyte’s emphasis on combination treatment strategies, integrating targeted therapies with chemotherapy, anti-angiogenic agents, and immunotherapies to enhance clinical outcomes. As several programs transition from early-phase clinical evaluation into late-stage Phase 3 development, the company continues to strengthen its position in precision oncology, with the goal of delivering new therapeutic options for patients facing cancers with historically poor prognoses and limited targeted treatment choices.
Source: Incyte press release
